<DOC>
	<DOCNO>NCT00358098</DOCNO>
	<brief_summary>This study hormone positive ( estrogen receptor [ ER ] ) , metastatic invasive ductal breast cancer look functional scan use positron emission tomography ( PET ) patient response hormone therapy . Functional scan allow investigator see one metastatic location . The investigator use estrogen base agent ( FES ) see number hormone positive metastasis compare positive lesion routine glucose ( FDG ) base scan . FES FDG-PET result compare give FDG FES ratio . The PET ratio calculate hormone therapy relapse treatment . The investigator biopsy accessible lesion FDG positive FES negative perform pathological test ER PR positivity compare original primary tumor ER/PR . The investigator test lesion tumor proliferation ( use Ki-67 ) aggressiveness use human epidermal growth factor receptor 2 ( HER-2 ) . Results compare primary tumor Ki-67 HER-2 determine concordance . The investigator pre-treatment result FES FDG-PET , calculate ratio , correlate primary metastatic lesion test ER/PR , Ki-67 , HER-2 , subsequent response therapy . The investigator determine FES-PET predictive value determine appropriateness hormone therapy metastatic disease . With result , investigator plan undertake future tumor biomarker/PET study metastatic breast cancer .</brief_summary>
	<brief_title>Study Determine Utility FES-PET FDG-PET Prediction Response Hormone Therapy Women With Estrogen Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>Primary objective : To determine utility pre-treatment ( 16 alpha [ 18-F ] -fluoroestradiol ) FES-PET routine ( [ 18-F ] -fluorodeoxy-D-glucose ) FDG-PET prediction response hormone therapy use standard response criterion ( RECIST ) gold standard 100 primary tumor hormone positive ( ER+ ) woman metastatic carcinoma breast . We measure standardize uptake ratio ( SUV ) FDG FES baseline correlate FDG/FES SUV ratio disease relapse . We predict increase FDG/FES ratio relapse use Pearson correlation coefficient examine regression equation slope measure change ratio . Twenty - forty patient core biopsy accessible FDG positive FES negative metastasis . Metastatic lesion immunohistochemistry ( IHC ) ER compare pretherapy FES result concordance . With 80 % agreement level negative FES negative core biopsy ER IHC 95 % confidence limit ( DI ) 56-94 % 20 64-90 % 40 patient respectively . Proliferative index tumor aggressiveness use IHC Ki-67 HER-2 respectively measure primary tumor biopsied metastatic lesion correlate metastatic disease response ( RECIST ) . Secondary objective regard HER-2 Ki-67 IHC response evaluate use Fisher 's exact test 2 X 2 table 100 woman 20-40 core biopsy . From sensitivity specificity determination , calculate observed agreement pretherapy FDG FES-PET ratio RECIST 86 % ( 95 % CI 78-92 % ) . Assuming 40 % response rate 100 woman receive first , second third line hormonal therapy RECIST response gold standard , choose 80 % sensitivity ( 95 % CI 64-91 % ) 90 % specificity ( 95 % CI 80-96 % ) give sufficiently robust data warrant study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Metastatic invasive ductal ER positive breast cancer All adjuvant treatment must complete least 3 month prior study entry . Patients primary tumor subtype invasive ductal adenocarcinoma Patients locoregional recurrence</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>PET</keyword>
	<keyword>hormone positive breast cancer</keyword>
</DOC>